הסימפוזיון הרפואי השנתי הרביעי בנושא ECD, פריז, צרפת

Apr 1, 2016

הסימפוזיון הרפואי השנתי הרביעי בנושא ECD, פריז, צרפת

ד"ר ג'וליאן הרוש
Boulevard de l'Hôpita
פריז, צרפת
1 באפריל 2016

תמונת קבוצה של הסימפוזיון הרפואי בפריז 2016

סיכום הסימפוזיון

ברית Erdheim-Chester Disease Global Alliance שמחה לספק את הסיכום הבא של ההרצאות שניתנו בסימפוזיון הרפואי הבינלאומי השנתי הרביעי בנושא ECD השנה, שהתקיים ב־15 בספטמבר 2016, ב־Hôpital Pitié-Salpêtrière בפריז, צרפת. הפגישה אפשרה לאנשי מקצוע רפואיים לשתף פעולה במחקר ECD, לחלוק ממצאים רפואיים ולדון בטיפול בחולים. תודה למארח המשותף של השנה, פרופסור Julien Haroche, MD, PhD; לכל המרצים ששיתפו את הנתונים והמומחיות שלהם במהלך דיוני הפאנל; לכל המשתתפים המעוניינים ללמוד עוד על ECD; ולכל המעורבים בתכנון והפיכת האירוע הזה להצלחה. תודה מיוחדת למתנדבים שיצרו סיכום זה עבור הקהילה ועבור אנשי המקצוע שלא יכלו להשתתף.

תוכניות עם סדר יום לסימפוזיון

מצגות

המצגות הבאות הוצגו במפגש 2016. בקרו בערוץ היוטיוב של ECD Global Alliance לצפייה בכל הסרטונים הקשורים ל-ECD שפורסמו.

主持人演示文稿幻灯片视频
Prof. Julien Haroche, MD, PhDWelcomeWelcome
Omar Abdel-Wahab, MD, PhD and Benjamin Durham, MD;Insights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine Models
洛伦佐·达尼亚，医学博士、哲学博士CCL18 in Erdheim-Chester Disease: Potential Implications in the Pathogenesis暂无
Matthew Collin, MDThe Hematopoietic Origin of Adult Histiocytosis暂无
Matthias Papo, MDErdheim-Chester disease is frequently associated with myeloproliferative neoplasms and myelodysplastic syndromes: a systematic clinical and molecular series of 189 patients暂无
Fleur Cohen-Aubart, MD & Wilfred Le Goff, MDMarked alteration of circulating immune cells in Erdheim-Chester disease in a large single-center series of 46 patients暂无
Roei D. Mazor, MDBiopsy Specimens of Erdheim-Chester Disease Patients暂无
菲利普·扬库，医学博士、哲学博士Clinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Tahla Munir, MDA Single- centre Experience of Treating Adult Patients with Langerhans' cell
Histiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease		A Single- centre Experience of Treating Adult Patients with Langerhans' cellHistiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease
Achille Aouba, MD, PhDSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester DiseaseSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester Disease
Tahla Munir, MDSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor VemurafenibSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor Vemurafenib
Fleur Cohen-Aubart, MD and Julien Haroche, MD, PhDThe LOVE trial: preliminary results暂无
朱维妮·埃斯特拉达-维拉斯 医学博士Dabrafenib and Trametinib as Potential Therapy in BRAF V600E Positive ErdheimChester Disease (ECD): Preliminary Results暂无
伊莱·L·戴蒙德，医学博士Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Preliminary Results暂无
Tahla Munir, MDDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case reportDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case report
Diana Melo, MDSpectrum of Cardiovascular Involvement in Erdheim-Chester Disease Evaluated by Multimodality Imaging暂无
Mark Heaney, MD, Julien Haroche, MD, PhD, Eli L. Diamond, MD, Matthew Collin, MD, Lorenzo Dagna, MD, PhDPanel Discussion: ECD Patient Registry: Community Tool for ResearchPanel Discussion: ECD Patient Registry: Community Tool for Research
Augusto Vaglio, MD, PhD, Juvianee Estrada-Veras, MD, Filip Janku, MD, PhD, Omar Abdel-Wahab, MD, PhD, Javier Martin, MD, PhDPanel Discussion: Proposed ECD GWAS StudyPanel Discussion: Proposed ECD GWAS Study
Corrado Campochiaro, MDManagement of ECD Symptoms and Side Effects of TreatmentsManagement of ECD Symptoms and Side Effects of Treatments
朱利奥·卡瓦利 医学博士Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester DiseaseAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease
卡琳·库蒂约，医学博士Endocrine manifestations in Erdheim-Chester diseaseEndocrine manifestations in Erdheim-Chester disease
Benjamin Durham, MDInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models
玛丽娜·费拉里尼 医学博士Tailoring Treatment for Erdheim-Chester Disease: Focus on ECDTailoring Treatment for Erdheim-Chester Disease: Focus on ECD
罗纳德·高 医学博士Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)
菲利普·扬库，医学博士、哲学博士Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Javier Martin, MD, PhDFuture Genetic Studies in Erdheim-Chester disease – GWAS StudyFuture Genetic Studies in Erdheim-Chester disease – GWAS Study
Kenneth McClain, MD, PhDElevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?
奥古斯托·瓦廖，医学博士、哲学博士MRI evidence of cardiac involvement in Erdheim-Chester diseaseMRI evidence of cardiac involvement in Erdheim-Chester disease
Julien Haroche, MD, PhD & Kathleen Brewer结束暂无